Verastem, Inc. (VSTM)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1526119 · fiscal year ends in Dec
Closing price $9.66 on 29 Oct 2026; 52-week range $3.45 to $10.64.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $874.1M
- Cash
- $136.4M
- Debt
- $74.0M
- Debt to equity
- 1.48
- Shares outstanding
- 90.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $30.9M | -$170.1M | -$209.5M | -$3.02 | – | 10-K filed 4 Mar 2026 |
| FY2024 | 31 Dec 2024 | $10.0M | -$115.0M | -$130.6M | -$3.66 | -$104.8M | 10-K filed 20 Mar 2025 |
| FY2022 | 31 Dec 2022 | $2.6M | -$72.9M | -$73.8M | -$4.56 | – | 10-K filed 14 Mar 2024 |
| FY2021 | 31 Dec 2021 | $2.1M | -$61.4M | -$71.2M | -$4.92 | -$53.7M | 10-K filed 14 Mar 2024 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $40.1M | -$34.7M | -$0.35 |
| Q1 FY2026 | 31 Mar 2026 | $18.7M | -$36.6M | -$0.46 |
| Q3 FY2025 | 30 Sep 2025 | $11.2M | -$98.5M | -$1.35 |
| Q2 FY2025 | 30 Jun 2025 | $2.1M | -$25.9M | -$0.62 |
| Q3 FY2024 | 30 Sep 2024 | $0 | -$24.0M | -$0.60 |
| Q2 FY2024 | 30 Jun 2024 | $10.0M | -$8.3M | -$0.31 |
| Q4 FY2022 | 31 Dec 2022 | $0 | -$16.8M | -$0.96 |
| Q3 FY2022 | 30 Sep 2022 | $0 | -$18.1M | -$1.08 |
Company events
The newest 8-K filings of 152 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 14 Oct 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 Oct 2026 | 8-K | Results, Leadership change, Investor update, Other events | 2.02, 5.02, 7.01, 8.01, 9.01 |
| 7 Aug 2026 | 8-K | Material agreement, New debt, Investor update | 1.01, 2.03, 7.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 17 Jun 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 26 May 2026 | 8-K | Shareholder vote | 5.07 |
| 7 May 2026 | 8-K | Investor update | 7.01, 9.01 |
| 4 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 4 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 8 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 31 Dec 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 334 held.
| Filed | Form | Period |
|---|---|---|
| 14 Oct 2026 | 8-K | 14 Oct 2026 |
| 14 Oct 2026 | 8-K | 12 Oct 2026 |
| 7 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 23 Jun 2026 | 8-K | 23 Jun 2026 |
| 17 Jun 2026 | 8-K | 16 Jun 2026 |
| 29 May 2026 | S-8 | – |
| 26 May 2026 | 8-K | 21 May 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 9 Apr 2026 | DEF 14A | 21 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 Oct 2026 | Paterson Dan, President and CEO | Sale under a trading plan | 44,121 | $8.00 | $353.0K | 652,712 | 2 Oct 2026 |
| 1 Oct 2026 | Calkins Daniel, Chief Financial Officer | Sale under a trading plan | 2,566 | $8.00 | $20.5K | 123,781 | 2 Oct 2026 |
| 21 Sep 2026 | Calkins Daniel, Chief Financial Officer | Sale under a trading plan | 55 | $7.70 | $424 | 118,014 | 23 Sep 2026 |
| 3 Aug 2026 | Paterson Dan, President and CEO | Sale under a trading plan | 1,302 | $5.81 | $7.6K | 589,940 | 5 Aug 2026 |
| 22 Jun 2026 | Paterson Dan, President and CEO | Sale under a trading plan | 20,871 | $4.18 | $87.2K | 591,242 | 24 Jun 2026 |
| 22 Jun 2026 | Calkins Daniel, Chief Financial Officer | Sale under a trading plan | 4,032 | $4.18 | $16.9K | 117,295 | 24 Jun 2026 |
| 22 Jun 2026 | Calkins Daniel, Chief Financial Officer | Sale under a trading plan | 57 | $4.13 | $235 | 117,238 | 24 Jun 2026 |
| 4 May 2026 | Paterson Dan, President and CEO | Sale under a trading plan | 806 | $5.82 | $4.7K | 612,113 | 6 May 2026 |
| 4 Feb 2026 | Paterson Dan, President and CEO | Sale under a trading plan | 970 | $6.69 | $6.5K | 612,919 | 5 Feb 2026 |
| 12 Jan 2026 | Paterson Dan, President and CEO | Sale under a trading plan | 10,321 | $7.16 | $73.9K | 400,104 | 14 Jan 2026 |
| 12 Jan 2026 | Calkins Daniel, Chief Financial Officer | Sale under a trading plan | 5,039 | $7.16 | $36.1K | 104,719 | 14 Jan 2026 |
| 24 Dec 2025 | Calkins Daniel, Chief Financial Officer | Sale under a trading plan | 80 | $7.86 | $629 | 109,758 | 29 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 1 Oct 2026 | Dan Paterson, Officer, Director | 44,121 | $353.0K | 1 Oct 2026 |
| 23 Jul 2026 | Gagnon Robert E., Director | 31,924 | $188.0K | 23 Jul 2026 |
| 25 Jun 2026 | Gagnon Robert E., Director | 21,492 | $90.5K | 25 Jun 2026 |
| 22 Jun 2026 | Dan Paterson, Officer, Director | 20,871 | $87.2K | 22 Jun 2026 |
| 27 May 2026 | Gagnon Robert E., Director | 20,103 | $87.6K | 27 May 2026 |
| 14 Jan 2026 | Dan Paterson, Officer | 5,039 | $36.1K | 12 Jan 2026 |
| 14 Jan 2026 | Dan Paterson, Officer, Director | 10,321 | $73.9K | 12 Jan 2026 |
| 9 Dec 2025 | Paterson Dan, Officer | 7,790 | $80.0K | 9 Dec 2025 |
| 21 Nov 2025 | Bunn Paul A., Board Member | 6,250 | $61.3K | 21 Nov 2025 |
| 21 Nov 2025 | Kauffman Michael, Board Member | 8,550 | $83.9K | 21 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Armistice Capital, LLC | 13G amended | 7.76% | 7.0M |
| 7 Aug 2026 | STATE STREET CORPORATION | 13G | 5.8% | 5.1M |
| 31 Jul 2026 | Vanguard Capital Management | 13G | 5.03% | 4.4M |
| 30 Jul 2026 | BlackRock, Inc. | 13G amended | 7% | 6.2M |
| 8 Jul 2026 | Polar Capital Holdings Plc | 13G amended | 4.8% | 3.7M |
| 15 May 2026 | RTW Investments, LP | 13G amended | 9.9% | 9.0M |
| 15 May 2026 | Balyasny Asset Management L.P. | 13G amended | 1.55% | 1.4M |
| 15 May 2026 | Armistice Capital, LLC | 13G amended | 5.23% | 4.6M |
| 15 May 2026 | Foresite Capital Fund VI LP | 13G amended | 3.6% | 3.1M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 17.2M | +14.95% | 2.49 |
| 30 Sep 2026 | 15.0M | -16.99% | 6.97 |
| 15 Sep 2026 | 18.0M | -1.47% | 6.52 |
| 31 Aug 2026 | 18.3M | -3.23% | 10.97 |
| 14 Aug 2026 | 18.9M | -4.62% | 9.63 |
| 31 Jul 2026 | 19.8M | -1.38% | 9.35 |
| 15 Jul 2026 | 20.1M | -16.73% | 6.83 |
| 30 Jun 2026 | 24.1M | +10.88% | 6.95 |
Funds that hold it
From each fund's latest Form 13F.
186 funds held it at 30 Jun 2026: 99 added and 34 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 9,192,447 | $35.1M | +2,997,522 |
| Nantahala Capital Management, LLC | 7,169,640 | $27.4M | – |
| Armistice Capital, LLC | 7,024,000 | $26.8M | +2,432,000 |
| RTW Investments, LP | 6,635,793 | $25.3M | +59,487 |
| Deep Track Capital, LP | 5,740,850 | $21.9M | 0 |
| State Street Corp. | 5,133,859 | $19.6M | +1,617,208 |
| Rosalind Advisors, Inc. | 3,986,509 | $15.2M | +1,848,034 |
| Vanguard Capital Management LLC | 3,851,508 | $14.7M | +528,738 |
| Stonepine Capital Management, LLC | 3,349,627 | $12.8M | +47,327 |
| Vanguard Portfolio Management LLC | 3,266,870 | $12.5M | +2,509,995 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B